Molecular diagnostics company, Great Basin Scientific, Inc. (NASDAQ:GBSN), announced on Monday that its common stock will begin trading on the OTC Market Group’s OTCQB marketplace effective at the open of the market on October 11, 2016. The trading symbol will remain GBSN. SALT LAKE CITY, Oct. 10, 2016 (GLOBE NEWSWIRE) — Great Basin Scientific, Inc. (GBSN), a molecular diagnostics company, announced today that its common stock will begin trading on […]Read More ˃
Several analysts have recently weighed in on BBCN Bancorp Inc (NASDAQ:BBCN), issuing notes to investors. Julianna Balicka of Keefe, Bruyette & Woods released a note on the stock 2 ago with a $16.00 price target. “BBCN is continuing to make progress in its strategy of winning banking business from U.S.-based subsidiaries of South Korean companies. As of June 30, BBCN had $1.15bn of commercial commitments outstanding with a utilization rate […]Read More ˃
A Look at Why RBC Capital Markets Lowered their Price Target on Flextronics International Ltd.(NASDAQ:FLEX) to $13 from $14.
On October 4 Equity Analysts Amit Daryanani, CFA, Mitch Steves and Associates Irvin Liu and Jeriel Ong of RBC Capital Markets Equity Research Lowered their Price Target on Flextronics International Ltd.(NASDAQ:FLEX) to $13 from $14. and Issued a report titled ”Adjusting Estimates To Reflect Challenging Macro In H2:15.” According to the report ”We are adjusting our estimates lower on FLEX to reflect multiple headwinds that we think will curtail revenue […]Read More ˃
The Inside Scoop on Why Deutsche Bank Reiterated their $36 Buy Rating on TerraForm Power Inc(NASDAQ:TERP)
On October 4 research analyst Vishal Shah and research associate Jerimiah Booream-Phelps Reiterated their $36 Buy Rating on TerraForm Power Inc(NASDAQ:TERP) and issued a report titled ”Takeaways from Management Meeting.” Overall thoughts on the meeting were ”We walked away incrementally more positive after meeting TERP management team. We expect concerns over near term capital raise to fade over the next few months as the company executes on closing the VSLR […]Read More ˃
Equity Research Firm Jefferies Reiterated its $3.50 price target on AcelRx Pharmaceuticals Inc(NASDAQ:ACRX) and Issued a Research Report titled ”ACRX: HOLD: Key Takeaways from R&D Day” on October 2. Equity Analysts Biren Amin, Hugo Ong, Ph.D., and Shaunak Deepak stated ”At its R&D Day, ACRX reviewed its pipeline portfolio which included a focus on ARX-04 which could be the next meaningful revenue opportunity. Based on clinical data and market research, […]Read More ˃
Equity Analyst Hartaj Singh of BTIG Equity Research reiterated his $12 price target on Progenics Pharmaceuticals, Inc.(NASDAQ:PGNX) October 3 in a research report titled ”Pipeline Focus Increasing.” According to Hartaj Singh ”PGNX is more than a play on Relistor royalties, with three mid/late stage assets that are positioning the company closer to creating a valuation rerating. Company management continues to demonstrate that they are building franchises that meet important unmet […]Read More ˃